Diabetes Diagnostics

Diabetes Diagnostics

Global Diabetes Diagnostics Market to Reach $39.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Diabetes Diagnostics estimated at US$26.3 Billion in the year 2020, is projected to reach a revised size of US$39.1 Billion by 2027, growing at a CAGR of 5.8% over the analysis period 2020-2027. Test Strips, one of the segments analyzed in the report, is projected to record a 7% CAGR and reach US$11.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Lancets segment is readjusted to a revised 6.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $7.1 Billion, While China is Forecast to Grow at 9.1% CAGR

The Diabetes Diagnostics market in the U.S. is estimated at US$7.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$8.4 Billion by the year 2027 trailing a CAGR of 9.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.1% and 5.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Analog Glucose Monitor Segment to Record 5.3% CAGR

In the global Analog Glucose Monitor segment, USA, Canada, Japan, China and Europe will drive the 4.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$2.8 Billion in the year 2020 will reach a projected size of US$3.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$5.3 Billion by the year 2027, while Latin America will expand at a 6.5% CAGR through the analysis period. We bring years of research experience to this 18th edition of our report. The 215-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

• A.Menarini Diagnostics Ltd.
• Abbott Diabetes Care Inc.
• Acon Laboratories Inc.
• AgaMatrix Inc.
• Apex Biotechnology Corporation
• ARKRAY Inc.
• Ascensia Diabetes Care Holdings AG
• B. Braun Melsungen AG
• Beckman Coulter Inc.
• Becton, Dickinson and Company
• BIONIME Corporation
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• DexCom Inc.
• Diazyme Laboratories Inc.
• EKF Diagnostics Holdings Plc
• HemoCue® AB
• LifeScan, Inc.
• Medtronic PLC
• Nova Biomedical Corporation
• OSANG Healthcare Co. Ltd.
• PTS Diagnostics
• Sanofi S.A.
• Sanwa Kagaku Kenkyusho Co Ltd.
• Siemens Healthineers
• Sinocare Inc.
• TaiDoc Technology Corporation
• Tandem Diabetes Care Inc.
• Terumo Corporation
• Tosoh Bioscience Inc.
• Trinity Biotech plc
• Trividia Health Inc.
• Ypsomed AG

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.